Addex Therapeutics Ltd

Healthcare · Biotechnology · Switzerland

Last price 3.09 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 3.35M

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Addex Therapeutics Ltd discovers, develops, and commercializes small-molecule pharmaceutical products for neurological disorders in Switzerland. The company focuses on the discovery of G-protein coupled receptors and enzymes. Its lead programs include Dipraglurant, which is in phase 1 clinical trial for the treatment of post-stroke/TBI recovery, as well as to treat Parkinson’s disease levodopa-induced dyskinesia. The company also develops ADX71149, which is in phase 1 for undisclosed indication; and GABAB PAM for the treatment pain, anxiety, ad...